Log in to search using one of your social media accounts:

 

Noden Pharma Announces FDA Approval of Tekturna (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
DUBLIN, Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 15, 2017 Category: Drugs & Pharmacology Source Type: news

Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
DUBLIN, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by t... Biopharmaceuticals, Cardiology, FDA Noden Pharma, Tekturna, aliskiren, Hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

Valturna (Aliskiren and Valsartan, USP Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 13, 2017 Category: Drugs & Pharmacology Source Type: news

Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 30, 2017 Category: Drugs & Pharmacology Source Type: news

Tekturna (Aliskiren Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2016 Category: Drugs & Pharmacology Source Type: news

Tekturna HCT (Aliskren and Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2016 Category: Drugs & Pharmacology Source Type: news

Tekamlo (Aliskiren and Amlodipine Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

PDL BioPharma Buys Novartis Hypertension Drugs
PDL BioPharma commits to equity investment in Noden Pharma for the acquisition of Tekturna and Tekturna HCT (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 25, 2016 Category: Pharmaceuticals Source Type: news

Aliskiren does not benefit heart failure patients with diabetes
Stephen FellerFLORENCE, Italy, May 23 (UPI) -- A hypertension drug thought to benefit heart failure patients with diabetes did not reduce the rate of death during a clinical trial, researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 23, 2016 Category: Consumer Health News Source Type: news

ATMOSPHERE: Aliskiren Not Superior to Enalapril in HFATMOSPHERE: Aliskiren Not Superior to Enalapril in HF
The negative trial came with a regulatory wrinkle, resulting in three responses being published with the study. The deputy editor admits this was "a bit usual," but so were the circumstances. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 20, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

ATMOSPHERE and the RAS Blockade Ceiling in Heart FailureATMOSPHERE and the RAS Blockade Ceiling in Heart Failure
Dr Pina interviews Prof McMurray about the trial on aliskiren and enalapril in HF and the perils of retrospective subgroup analyses. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2016 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news

News from ACC.16: ATMOSPHERE, Antiarrhythmics for Out-of-Hospital Cardiac Arrest, and More (FREE)
By the Editors For the past few days, NEJM Journal Watch has been bringing you breaking news from the American College of Cardiology's annual meeting in Chicago. Take a look at the latest: Aliskiren for Heart Failure: In the randomized ATMOSPHERE trial, adding the direct renin … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 4, 2016 Category: Primary Care Source Type: news

ATMOSPHERE: Heart Failure Trial Poisoned By Controversy (CME/CE)
(MedPage Today) -- Aliskiren raised regulatory pandemonium as it crashed in trials (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 4, 2016 Category: American Health Source Type: news

ATMOSPHERE: Heart Failure Trial Tainted By Controversy (CME/CE)
(MedPage Today) -- Aliskiren raised regulatory turmoil as trouble arose in trials (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 4, 2016 Category: American Health Source Type: news

No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
(American College of Cardiology) In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported at the American College of Cardiology's 65th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2016 Category: Global & Universal Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Nueva advertencia y contraindicaciĆ³n sobre medicamentos para la presiĆ³n arterial que contienen aliskiren
El 20 de abril del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) advirtió sobre la probabilidad de riesgos por el uso de medicamentos para la presión arterial que contienen aliskiren combinado con otros medicamentos denominados inhibidores de la enzima convertidora de angiotensina (ACEIs por sus siglas en inglés), y los bloqueadores de los receptores de angiotensina (ARBs por sus siglas en inglés) en pacientes con diabetes o problemas renales o de riñón. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

CardioBreak: Statins and Sex, Tekturna Black Box
(MedPage Today) -- Recent developments of interest in cardiovascular medicine. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 13, 2015 Category: Cardiology Source Type: news

Aliskiren and Antihypertensives in Elderly With HypertensionAliskiren and Antihypertensives in Elderly With Hypertension
Does BP lowering reduce cardiovascular disease in elderly individuals with SBP (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 7, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

BP, Cholesterol Drugs Recalled Over Contamination FearsBP, Cholesterol Drugs Recalled Over Contamination Fears
Novartis has sent letters to physicians informing them that free samples of Diovan, Tekturna, Lescol, and other drugs may have been contaminated by a chemical in their packaging. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2013 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Aliskiren and Outcomes in Diabetic vs Non-diabetics With HFAliskiren and Outcomes in Diabetic vs Non-diabetics With HF
Learn more about effects of a direct renin inhibitor on post-discharge outcomes in patients hospitalized for heart failure. European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Blood pressure drug tends to slow coronary disease research finds
Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research). The researchers found that the renin-inhibitor aliskiren tended to slow coronary disease progression and reduced the risk of death, stroke and heart attack in these patients by about 50 percent, compared to placebo, suggesting that patients with prehypertension may benefit from blood pressure lowering drugs... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Medication does not slow progression of coronary disease in patients with prehypertension
Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 5, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Blood pressure lowering drug aliskiren did not improve coronary artery disease for patients with prehypertension AQUARIUS study finds
The blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) reveal... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 5, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Aliskiren: No impact on atherosclerosis progression in AQUARIUS
In a new setback for the drug, the renin-inhibitor has failed to demonstrate atherosclerosis regression in patients with prehypertension. (Source: theHeart.org)
Source: theHeart.org - September 3, 2013 Category: Cardiology Source Type: news

ESC: No Plaque Regression With Aliskiren (CME/CE)
AMSTERDAM (MedPage Today) -- Giving the direct renin inhibitor aliskiren (Tekturna) to patients who have coronary artery disease -- but don't meet clinical criteria for hypertension -- did not slow progression of atherosclerosis, researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 3, 2013 Category: Cardiology Source Type: news

Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
(European Society of Cardiology) The blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound study reveal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2013 Category: Global & Universal Source Type: news

Medication does not slow progression of coronary disease in patients with prehypertension
(The JAMA Network Journals) Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2013 Category: Global & Universal Source Type: news

Aliskiren No Help in HF if Kidneys Impaired (CME/CE)
LISBON (MedPage Today) -- Renal function got worse when aliskiren (Tekturna) was given on top of standard therapy with ACE inhibitors or angiotensin receptor blockers to patients with heart failure and renal impairment, a small trial showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 28, 2013 Category: Consumer Health News Source Type: news

MRI evidence of plaque progression in aliskiren-treated patients
Although the totality of the evidence did show a significantly increased risk of plaque progression with aliskiren, the increase was driven by a change in aortic plaque among individuals treated with it in combination with an ACE inhibitor or angiotensin-receptor blocker. (Source: theHeart.org)
Source: theHeart.org - May 23, 2013 Category: Cardiology Source Type: news

Atherosclerosis and AliskirenAtherosclerosis and Aliskiren
Although the totality of the evidence did show a significantly increased risk of plaque progression with aliskiren, the increase was driven by a change in aortic plaque among individuals treated with it in combination with an ACE inhibitor or angiotensin-receptor blocker. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 22, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aliskiren disappoints in heart failure patients
Adding aliskiren to the standard therapy of patients hospitalized for heart failure with reduced left ventricular ejection fraction does not reduce their risk for cardiovascular mortality or readmission, shows the ASTRONAUT trial. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - March 18, 2013 Category: Cardiology Source Type: news

BP Drug Flops in Heart Failure (CME/CE)
(MedPage Today) -- The blood pressure drug aliskiren (Tekturna) doesn't help prevent rehospitalization or death for heart failure patients, the ASTRONAUT trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 13, 2013 Category: Cardiology Source Type: news

Viagra, Aliskiren Not Helpful for Heart Failure After All: Studies
Title: Viagra, Aliskiren Not Helpful for Heart Failure After All: StudiesCategory: Health NewsCreated: 3/11/2013 4:36:00 PMLast Editorial Review: 3/12/2013 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 12, 2013 Category: Cardiology Source Type: news

RCT: Effect of aliskiren on postdischarge mortality and heart failure readmissions - results from the ASTRONAUT study
Source: JAMA Area: News The Journal of the American Medical Association has featured a study evaluating the addition of aliskiren (a direct renin inhibitor) to standard therapy in the management of patients with heart failure and its effects on the rate of cardiovascular death or rehospitalisation due to heart failure (HF).   The double-blind, placebo-controlled study involved patients with haemodynamically stable HF after a median of 5 days after admission into hospital. Eligible patients were 18 years or older with left ventricular ejection fraction (LVEF) 40% or less, elevated natriuretic peptides (brain natri...
Source: NeLM - Cardiovascular Medicine - March 12, 2013 Category: Cardiology Source Type: news

Aliskiren Flops as Add-On Therapy in Systolic HFAliskiren Flops as Add-On Therapy in Systolic HF
Signals of biomarker improvement and a differential clinical effect by diabetes status are highlights of the trial, but not efficacy for the primary end point: six-month CV death or heart-failure rehospitalization. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 11, 2013 Category: Cardiology Tags: Cardiology News Source Type: news

Viagra, Aliskiren Not Helpful for Heart Failure After All
Results surprise, disappoint scientists Source: HealthDay Related MedlinePlus Page: Heart Failure (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 11, 2013 Category: Consumer Health News Source Type: news

Direct renin inhibitor aliskiren flops as add-on therapy in systolic HF: ASTRONAUT
Signals of biomarker improvement and a differential clinical effect by diabetes status are highlights of the trial, but not efficacy for the primary end point: six-month CV death or heart-failure rehospitalization. (Source: theHeart.org)
Source: theHeart.org - March 11, 2013 Category: Cardiology Source Type: news

Meta-analysis: Efficacy and safety of dual blockade of the renin-angiotensin system
The objective of the current systematic review and meta-analysis was to compare the long term efficacy of dual RAS blockade (any two of ACE inhibitors, angiotensin receptor blockers, or aliskiren) with monotherapy, and to evaluate adverse events in patients receiving dual therapy compared with monotherapy. A systematic literature search (PubMed, Embase, Cochrane central register of controlled trials; Jan 1990-Aug 2012; no language restriction) identified 33 RCTs (total n=68,405; 71% men) reporting the outcomes of ... (Source: NeLM - Cardiovascular Medicine)
Source: NeLM - Cardiovascular Medicine - January 29, 2013 Category: Cardiology Source Type: news

Novartis Says U.S. Unit Subpoenaed
Novartis said its U.S. unit has been subpoenaed as part of a federal investigation into the company's marketing of blood-pressure drug Tekturna and other products. (Source: WSJ.com: Health)
Source: WSJ.com: Health - January 24, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news